Hear about developments in in silico technology, as well as experimental approaches useful for accurately predicting and modeling the structures of proteins in structure-based drug design efforts. In addition,examples of successful applications of such technology approaches to genome-to-drug lead investigations will be addressed.

1. Final Agenda June 19-21, 2013 • The Revere Hotel • Boston, MA
Cambridge Healthtech Institute and Bio-IT World’s Thirteenth Annual
Structure-Based
Drug Design
Genome to Drug Lead
with Big Data Approach
Keynote Presentation:
Drugging the Undruggable: Transforming
Nature’s α-Helix into Breakthrough Medicines
Tomi Sawyer, Ph.D., CSO, Aileron Therapeutics
Corporate Sponsors:
Register by March 22
& save up to $350!
Organized by:
Cambridge Healthtech Institute healthtech.com/SBD

2. Structure-Based
Drug Design
Dear Colleague,
Thank you for your continued interest and support Who You Will Meet
regarding our Structure-Based Drug Design conference. Titles:
• Lab Head/Head
The growing protein structure information has given structure-based methods a place of
• Team Leader
prominence in drug discovery. The current state of in silico technology for effectively using
• Chief Scientific Officer
biological big data for structure-based drug design is significantly limited by the lack of
• Director
a realistic environment for simulations and an absence of fully integrated infrastructure.
• Research Scientist/Principal Scientist/
Moreover, the emerging deluge of biological data of all kinds available to the field of Scientist
biomedicine and the pharmaceutical industry represents a significant opportunity to • Senior Researcher/Researcher
fundamentally change the process of disease target discovery and drug design. • Graduate Student
• Professor
Leveraging ever-increasing computing power and large-scale informatics framework that • PostDoc
integrate functional, structural and expression information, we face ample opportunities to
fine-tune our protein-ligand modeling algorithm and modify the molecule to get the desired
properties. Departments:
• Biochemistry
In silico approaches to rational structure-based drug discovery are leveraging big data • Bioinformatics
technology in the identification and optimization of lead compounds and the identification • Chemical Biology
and validation of drug targets, followed by the prediction of ligands for the target protein • Chemistry
from molecular modeling computation. • Computational Biology
• Computational Chemistry
At CHI’s thirteenth annual Structure-Based Drug Design conference, you will hear about • Discovery Chemistry
developments in in silico technology, as well as experimental approaches useful for accurately • Drug Discovery
predicting and modeling the structures of proteins in structure-based drug design efforts. • Informatics
In addition, examples of successful applications of such technology approaches to • Lead Discovery
genome-to-drug lead investigations will be addressed. • Medicinal Chemistry
• Molecular Modeling
• Scientific Computing
Register by March 22 at the early rate and save up to $350 off • Stuctural Biology
your conference registration. • Structural Chemistry
• Structural Sciences
Warmest regards,
Co-Located Event:
Eleventh Annual
Ming Guo
Next-Gen
Conference Director
Kinase Inhibitors:
Cambridge Healthtech Institute “Given both the overwhelming amount of available data
Moving Towards a Successful Pipeline
and the fact that traditional pharma approaches to
innovation seem to have largely run out of steam, a bet June 17-19
on big data analytics might make a lot of sense now.” healthtech.com/KIN
- David Shaywitz, M.D., Ph.D., Physician, Scientist and Best Value! Register for the
Management Consultant Structure-Based Drug Design
and Kinase conferences at a
special rate.
2 ••• healthtech.com/SBD

3. WEDNESDAY, JUNE 19 THURSDAY, JUNE 20
STRUCTURE-BASED DRUG DESIGN FOR KINASE 7:30 am Morning Coffee
1:15 pm Chairperson’s Opening Remarks 8:30 Chairperson’s Remarks
1:20 Structure-Based Design of Potent and Selective inhibitors of PI3-Kinase Delta »»
KEYNOTE PRESENTATION:
Jeremy M. Murray, Ph.D., Scientist, Structural Biology, Genentech 8:40 Drugging the Undruggable: Transforming Nature’s α-Helix into
Inhibition of PI3Kδ is considered to be an attractive mechanism for the treatment of
inflammatory diseases and leukocyte malignancies. Using a structure-based design
Breakthrough Medicines
approach, we have identified a series of potent and selective inhibitors of PI3Kδ. Tomi Sawyer, Ph.D., CSO, Aileron Therapeutics
These inhibitors do not occupy the induced selectivity pocket between Trp760 and A major challenge of drug discovery has been to successfully
Met752 that is observed for other families of selective PI3Kδ inhibitors. Instead, modulate the biological properties of those therapeutic targets
the selectivity of the compounds for inhibition of PI3Kδ relative to other PI3K deemed “undruggable” as defined relative to small-molecules.
isoforms appears to be due primarily to the strong interactions these inhibitors However, recent advancements leveraging peptides and macrocycles are
are able to make with Trp760 in the PI3Kδ binding pocket. This talk will discuss expanding such drug space, especially for many intracellular protein–protein
the structural understanding of the selectivity of these inhibitors against other interaction targets deemed “hot” drug-wise. Structural biology and computational
isoforms, pharmacokinetic properties and the ability of select compounds to inhibit chemistry are key tools for such drug discovery. As a case study, advancements
the function of B-cells in vivo. in stapled peptide technology to transform Nature’s α-helix into breakthrough
medicines will be presented.
1:50 MD Simulations of Mutant and WT PI3Kα: Insights into the Mechanism
of Overactivation and Implications for Drug Design 9:10 A Beacon in the Dark: Structural Information in the Absence of Structure
Zoe Cournia, Ph.D., Investigator, Biomedical Research Foundation, Academy of Athens Edward R. Zartler, President and CSO, Quantum Tessera Consulting, LLC
The current (and next) generation of drug targets are very difficult
PI 3 kinase alpha (PI3Kα) is one of the most frequently mutated proteins in human
to ligand: membrane proteins, multimeric protein complexes,
cancers. Molecular dynamics simulations in aqueous solution performed for wild
post-translationally modified proteins, protein-protein interactions.
type (WT) and H1047R mutant PI3Kα proteins, revealed different dynamical and
Advances in structural biology have been made where we can obtain
structural features for the two proteins, which may lead to kinase overactivation in
high resolution structural information for many of these targets. However, for a
the mutant variant. Binding site prediction and virtual screening further facilitated
large swath of the current, and next-gen targets, we are simply working in the
the development of novel mutant-specific PI3Kα inhibitors that exploit the altered
structural dark. Recent advances in NMR-based methods, coupled with novel ideas
conformation of the mutant with respect to the WT protein.
in fragment-based hit generation, can now shine a light into this darkness, yielding
crucial structural details to allow ligands to be rationally designed. We will discuss
2:20 Sponsored Presentation (Opportunity Available) these advances and their application to drug discovery.
2:50 Refreshment Break in the Exhibit Hall with Poster Viewing FORCE FIELD CALCULATION
DRUG RESISTANCE 9:40 Docking: Is It Possible to Know When It Works?
Greg Warren, Ph.D., Senior Applications Scientist,
3:30 Sponsored Presentation (Opportunity Available)
OpenEye Scientific Software, Inc.
It is commonly held that the same, protein-centric approach, can be used
4:00 Towards a New Generation of Animicrobial Antifolates successfully both to predict the bound conformation of a ligand in complex with a
Dennis L. Wright, Ph.D., Professor of Pharmaceutical Sciences and given protein (pose prediction) and to rank molecules based on their probability of
Chemistry, University of Connecticut being a binder to that protein (structure-based virtual screening). We will present
We are using a structure-based design approach to develop potent tools in the OEDocking Suite that approach these two problems as issues of a
and selective inhibitors of the enzyme dihydrofolate reductase (DHFR) rather different nature. Successful results in virtual screening using the rigid protein
from a variety of pathogenic organisms. Analysis of crystal structures approximation in docking will be presented along with a flexible, ligand-centric
of trimethoprim-resistant and naturally-insensitive enzymes led to the design of a approach to pose prediction that is much more reliable than traditional protein-
series of propargyl-linked antifolates characterized by high potency, good selectivity centric posing tools. We also show that whether the problem is pose prediction or
over the human form of the enzyme and good anti-microbial activity. virtual screening, combining ligand and protein information in the same calculation
produces better results.
4:30 Understanding Drug Mechanism of Action by Target Gene Overexpression
Adam C. Palmer, Ph.D., Postdoctoral Fellow, Department of Systems 10:10 Coffee Break in the Exhibit Hall with Poster Viewing
Biology, Harvard Medical School
The molecular targets of drugs can sometimes, but not always, 10:40 Incorporating Ligand Polarisation in Binding Free Energy Calculations
be identified amongst genes that confer drug resistance when Jonathan W. Essex, Ph.D., Professor, Head, Computational Systems
overexpressed. We quantitatively overexpressed genes encoding Chemistry, Chairman, Institute for Complex Systems Simulation (ICSS),
known antibiotic targets and observed that drug resistance does not only increase; School of Chemistry, University of Southampton
it can remain unchanged, decrease, or even have a non-monotonic dependence on While the methods underpinning the calculation of protein-ligand
target expression. These diverse effects are explained by simple models considering binding free energies are well understood, accurate calculations are
gene toxicity and drug-induction of harmful target-catalyzed reactions. The relation still fundamentally limited by inadequate sampling of the protein-ligand complex,
between drug resistance and target expression may reveal unexpectedly complex and inaccurate modeling of the associated intermolecular interactions. To address
mechanisms of drug action. the second issue, we have developed a simple and computationally inexpensive
correction to the calculated free energies based on a hybrid quantum mechanics/
5:00 Close of the Day molecular mechanics approach. In this presentation, the method will be described
and its performance assessed in the calculation of small and drug-like molecules’
free energies of hydration, and on the calculation of protein-ligand binding affinities
Dinner Short Course (June 19, 6:00-8:00 pm)* in neuraminidase, CDK2 and COX2.
Structure-Based Drug Design for Epigenetic Targets
Johnathan R. Whetstine, Ph.D., Assistant Professor of Medicine, Harvard Medical School
Philip Fallon, Ph.D., Senior Medicinal Chemist, Domainex Ltd.
*Separate registration required.
healthtech.com/SBD ••• 3

4. 11:10 Site Identification by Ligand Competitive Saturation (SILCS): Structure- a significant portion of the total binding energy, and thus represent opportunities
Based Free Energy Computational Approach for Ligand Discovery for ligand design. Computing desolvation energetics typically requires lengthy
simulations, but this talk presents a fast and easy-to-use method (3D-RISM) which
and Optimization computes desolvation energies in minutes, without using explicit simulations.
Alexander D. MacKerell, Jr., Ph.D., Grollman-Glick Professor of Application to ligand optimization is demonstrated using case studies.
Pharmaceutical Sciences, Director, Computer-Aided Drug Design Center,
School of Pharmacy, University of Maryland 3:10 Refreshment Break in the Exhibit Hall with Poster Viewing
The Site Identification by Ligand Competitive Saturation (SILCS) method uses
explicit solvent all-atom molecular dynamics simulations to identify binding sites
3:40 Characterizing and Exploiting the Solvation of Protein Surfaces for
on proteins for functional group classes based on rigorous free energy criteria that
includes protein flexibility and fragment desolvation. Information from the SILCS Applications in Drug Design and Discovery
approach, termed FragMaps, may be used for the identification of novel ligands Tom Kurtzman Young, Ph.D., Assistant Professor, Department of Chemistry, Lehman
targeting protein, including de novo ligand design. In addition, the SILCS method College, CUNY
may be combined with structural information on a ligand-protein complex to The displacement of water from a binding site by a ligand is a principal, and often
facilitate modification of the ligand to improve its binding affinity. dominant, source of binding free energy. In recent years, a number of techniques
based on Inhomogeneous Solvation Theory have been developed that map out the
11:40 Blurring to Bring Binding Free Energies into Focus solvation thermodynamics of protein binding sites (STOW, WaterMap, GIST). We
outline the physical basis of these mapping techniques and present some possible
Kenneth M. Merz, Jr., University of Florida Research Foundation Professor, applications in drug discovery and design.
Edmund H. Prominski Professor of Chemistry, Department of Chemistry,
Quantum Theory Project, University of Florida 4:10 Mapping Protein Surfaces with MixMD to Identify New Binding Sites
Docking calculations coupled with binding free energy estimates
(scoring) are a mainstay of structure-based drug design. This talk Heather Carlson, Professor, Medicinal Chemistry, University of Michigan
addresses how to use ensemble principles to estimate and reduce uncertainty of Mixed-solvent molecular dynamics (MixMD) is an emerging technique in
computed binding free energies. We have developed methods to evaluate potential structure-based drug design (SBDD). The most significant benefits are the
function error and in this talk we will demonstrate how to use this knowledge to ability of a protein to adapt in the presence of a probe and the identification
improve the outcome of a docking and scoring exercise. This was accomplished via of binding sites where organic molecules specifically out-compete water.
the development of novel scoring approaches that employ statistical mechanical Rather than ignoring the complicated role of water as most SBDD methods do, it is truly
principles and are coupled with error propagation. Importantly, our approach yields embraced in MixMD. Blinded, experimental validation of the method will be presented.
free energies as well as estimates of the random and systematic errors in these
quantities, providing insight into the reliability of the computed free energies. 4:40 The Potency-Insolubility Conundrum in Drug Discovery: Mechanism and
Solution for Hepatitis C Inhibitors
12:10 pm Luncheon Presentation (Opportunity Available) Patrick R. Connelly, Ph.D., Principal Scientific Fellow, Vertex
or Lunch on Your Own Pharmaceuticals, Inc.
As compounds are optimized for greater potency during
GPCR pharmaceutical discovery, their aqueous solubility often decreases,
making them less viable as orally-administered drugs. The potency-insolubility
1:30 Chairperson’s Remarks conundrum has prompted speculation, concern, and attempts to taxonomize
the problem or overcome it technologically. However, a fundamental molecular
connection between binding potency and aqueous insolubility has yet to be
1:40 An Automated Pipeline for the Modeling and Simulation of GPCRs:
elucidated. By examination of the structural and thermodynamic properties
Applications to Structure-Based Drug Design of telaprevir, a sparingly soluble inhibitor of the NS3 protease of the Hepatitis
Hugo Gutierrez-de-Teran, Ph.D., Parga Pondal Research Fellow, C virus, it is revealed that potency and insolubility share a common origin. A
Bioinformatics, Public Galician Foundation of Genomic Medicine design strategy based on supramolecular graph set considerations provides a
The recent advances in membrane protein crystallography have generalizable solution to the conundrum.
provided extremely valuable structural information of the superfamily
of G-protein-coupled receptors (GPCRs). Recently, we have developed GPCR- 5:10 Welcome Reception in the Exhibit Hall with Poster Viewing
ModSim (http://gpcr.usc.es), a web-based, automated pipeline to generate high-
quality 3D models of the remaining GPCRs and to perform molecular dynamics
(MD) simulations with an explicit representation of the cellular membrane, 6:30 End of Day
structural water, cholesterol or lipid molecules. With this computational tool,
research groups without prior experience in computational chemistry can set up FRIDAY, JUNE 21
ambitious projects on SBDD in GPCRs in a systematic and comprehensive way.
7:30 am Breakfast Roundtable Discussions
2:10 How Drugs Bind and Control Their Targets: Characterizing GPCR
Signaling through Long-Timescale Simulation FRAGMENT-BASED DRUG DESIGN
Ron O. Dror, Senior Research Scientist, D. E. Shaw Research
One-third of drugs act by binding to G protein–coupled receptors 8:30 Chairperson’s Remarks
(GPCRs) and either triggering or preventing receptor activation, but the
process by which they do so has proven difficult to characterize either 8:40 Case Histories of Recent Fragment-Based Drug Discovery Projects
experimentally or computationally. Anton, a special-purpose machine that we
designed to accelerate molecular dynamics simulations by orders of magnitude, Christopher W. Murray, Ph.D., Vice President, Discovery Technology, Astex
has enabled simulations in which drugs spontaneously associate with GPCRs Pharmaceuticals
to achieve bound conformations that match crystal structures almost perfectly. Here we describe some case histories of applying fragment-based
Anton simulations have also captured transitions of a GPCR between its active and drug discovery to challenging drug targets. This will include the design
inactive states, allowing us to characterize the mechanism of receptor activation. of protein-protein interaction inhibitors of IAP family proteins and the
Our results suggest opportunities for the design of drugs that achieve greater design of allosteric inhibitors of full-length NS3 proteins from the Hepatitis C Virus.
specificity and control receptor signaling more precisely. The presentation will discuss the difficulties associated with applying fragment-
based drug discovery to challenging target classes and will discuss ways in which
these can be mitigated.
WATER & SOLVATION IN DRUG DESIGN
2:40 Exploiting Solvent Effects in Drug Design and Optimization
Sponsored by 9:10 Computational Protein Mapping to Drive the Development of Fragment
Chris Williams, Ph.D., Principal Scientist, Chemical Computing Group Hits into Leads
Upon ligand binding, solvent molecules around the binding pocket Sandor Vajda, Ph.D., Professor of Biomedical Engineering and Chemistry, Director,
and the ligand become displaced or rearranged. These desolvation energies can be Biomolecular Engineering Research Center, Boston University
healthtech.com/SBD ••• 4

5. Fragment-based drug design (FBDD) starts with finding fragment-sized compounds A promising way to interfere with biological processes is through the control of
that are highly ligand efficient and can serve as a core moiety for developing protein-protein interactions by means of small molecules. Recent advances in the
high-affinity leads. Although the core-bound structure of a protein facilitates the understanding of the energetics and dynamics of protein-binding interfaces open
construction of leads, effective design is far from straightforward. We show that up a way to apply rational design approaches for finding protein-protein interaction
protein mapping, a computational method developed to find binding hot spots, modulators (PPIM). Here, we successfully identify small-molecule inhibitors of the
provides information that complements the fragment screening results and can dimer to tetramer transition of the NHR2 domain within the RUNX1/ETO fusion
drive the evolution of core fragments into larger leads with a minimal loss or, in protein, a novel target for the treatment of acute myeloid leukemia.
some cases, even a gain in ligand efficiency.
2:30 Structure-Based Guided Development of Focused Chemical Library
9:40 Determination of Binding Poses, Kinetics and Energetics in Fragment- Dedicated to Orthosteric Modulation of Protein-Protein Interactions
Based Design Xavier Morelli, Ph.D., Group Leader, Cancer Research Center of Marseille,
Gianni De Fabritiis, Ph.D., Computational Biophysics Laboratory (GRIB- CNRS
IMIM), Universitat Pompeu Fabra, Barcelona Biomedical Research Park This talk will address some challenging issues: biological and
(PRBB) chemical spaces of PPI with known orthosteric inhibitors, ligandability
assessment of protein-protein interactions, design and validation of
chemical libraries dedicated to PPIs.
10:10 Coffee Break in the Exhibit Hall with Poster Viewing
3:00 Refreshment Break
10:40 The Tip of the Iceberg and the Chemical Universe: Fuzzy Hit Finding
Under Synthetic Feasibility Conditions EPIGENETIC TARGETING
Carsten Detering, Ph.D., CEO, BioSolveIT, Inc.
We have come up with a method that addresses the problem of
3:15 Design and Develop Bromodomain Inhibitor for Cancer Therapy
crowded patent space. It captures existing available chemistry in a Jun Qi, Ph.D., Senior Research Scientist, Medical Oncology, Dana-Farber
company and thus allows the researcher to fuzzily search in a larger Cancer Institute
portion of the chemical universe available to him/her. Results are returned with In cancer, epigenetic proteins are promising and intensely studied
their underlying chemical synthesis, which renders retro-synthesis unnecessary. targets for therapeutic drug discovery. Among the chromatin-
Time saved can be invested in other Medicinal Chemistry efforts. The talk will modifying enzymes, so-called epigenetic “writers” “readers” and
,
highlight the method as well as several application examples. “erasers” chromatin-binding modules or epigenetic “readers” have received
,
comparatively little attention perhaps owing to perceptions regarding the difficulty
of targeting protein-protein interactions. Motivated by this challenge, we have
11:10 Advances in Predicting Protein-Protein Binding Sponsored by
developed first-in-class, drug-like inhibitors of “bromodomain and extraterminal
Affinity and Protein Stability domain” epigenetic readers (BETs) for mechanistic study and therapeutic
Woody Sherman, Ph.D., Vice President, Applications application in cancer. We are continuously integrating the transcriptional
Science, Schrodinger, Inc. consequences of BETi with changes in the epigenomic landscapes of cancer cells
to elucidate the mechanisms underlying response to BETi using chemical and
genetic perturbations.
11:40 Sponsored Presentation (Opportunity Available)
3:45 The Impact of Structural Data on Epigenetic Probe Discovery for the
12:10 pm Luncheon Presentation (Opportunity Available) Public Domain
or Lunch on Your Own Dafydd Owen, Ph.D., Associate Research Fellow, Biotherapeutics
Worldwide R&D, Pfizer Worldwide Medicinal Chemistry
PROTEIN-PROTEIN INTERACTION Research into the role of epigenetics in disease could be significantly
accelerated if cell-active chemical probes for such targets were
1:25 Chairperson’s Remarks available to the research community, through a collaborative, open-
innovation model. Pfizer is a member of a public-private partnership led by the
1:30 How Does a Small-Molecule Inhibitor Bind at the Protein-Protein Structural Genomics Consortium (SGC) to help identify a suite of high-quality
chemical probes for epigenetic targets. This partnership is unique in that it brings
Interface of Interleukin 2? the medicinal chemistry expertise within industry together with biological expertise
Yibing Shan, Senior Scientist, DE Shaw Research in academia to drive basic research in an emerging area of important biology of
potential relevance to many diseases. The impact of structural biology on probe
discovery will be presented.
2:00 From Determinants of RUNX1/ETO Tetramerization to Small-Molecule 4:15 Closing Remarks
Protein-Protein Interaction Inhibitors Targeting Acute Myeloid
Leukemia 4:30 End of Conference
Holger Gohlke, Ph. D., Professor, Institute of Pharmaceutical and
Medicinal Chemistry, Heinrich-Heine-University, Düsseldorf
Sponsoring Society: Media Partners:
Media Sponsor:
5 ••• healthtech.com/SBD

6. Sponsorship & Exhibit
CHI offers comprehensive sponsorship packages which include presentation
opportunities, exhibit space and branding, as well as the use of the pre- and
post-show delegate list. Sponsorship allows you to achieve your objectives
Information before, during, and long after the event. Any sponsorship can be customized
to meet your company’s needs and budget. Signing on earlier will allow you
to maximize exposure to hard-to-reach decision makers.
Agenda Presentations
Showcase your solutions to a guaranteed, highly-targeted audience.
Package includes a 15- or 30-minute podium presentation within
Looking for additional ways to
the scientific agenda, exhibit space, on-site branding and access to
cooperative marketing efforts by CHI.
drive leads to your sales team?
CHI can help with custom lead
Breakfast & Luncheon Presentations
Opportunities include a 30-minute podium presentation. Boxed lunches generation programs!
are delivered into the main session room, which guarantees audience
attendance and participation. A limited number of presentations are We offer clients numerous options for custom lead generation programs to
available for sponsorship and they will sell out quickly. Sign on to address their marketing and sales needs. Some of our programs include: live
secure your talk! webinars, white papers, market surveys, podcasts, and more!
Invitation-Only VIP Dinner/Hospitality Suite Benefits of working with CHI for your lead
Sponsors will hand-pick their top prospects from the conference generation needs:
pre-registration list for an evening of networking at the hotel or at a • Your campaign will receive targeted promotion to CHI’s unparalleled
choice local venue. CHI will extend invitations and deliver prospects. database of over 800,000 individuals, all of which are involved in
Evening will be customized according to sponsor’s objectives (i.e. all sectors of the life sciences – lists can be segmented based on
purely social, focus group, reception style, or plated dinner with geography, research area, title and industry
specific conversation focus).
• All custom lead generation programs are promoted through our
experienced marketing team that will develop and drive targeted
Focus Groups campaigns to expand awareness and bolster leads
CHI can help you organize and execute a focus group on site. This
• For our webinar programs, we offer assistance in procuring speakers for
exclusive gathering can be useful to conduct market research, gain
your web symposia through our extensive roster of industry recognized
feedback on a new product idea, and gather marketing intelligence from
speakers across multiple disciplines within life sciences, as well as
industry experts on a specific topic. Please inquire for more details.
provide an experienced moderator and dedicated operations team to
coordinate all efforts
User Group Meeting
• If choosing a white paper program, we can offer editorial experience and
Co-locate your user group with the Structure-Based Drug Design
provide an industry-recognized author to write your white paper
conference. CHI will help market the event, manage logistical
operations, develop an agenda, and more. CHI can handle the entirety
of the meeting, or aspects of your choice.
Exhibit Information
Exhibitors will enjoy facilitated networking opportunities with qualified
decision-makers at the Structure-Based Drug Design conference, making
it the perfect platform to launch a new product, collect feedback and For additional sponsorship &
generate new leads. Exhibit space sells out quickly, so reserve yours
today! exhibit information, please contact:
Additional Promotional Opportunities Include:
• Conference tote bags Jon Stroup
• Badge lanyards
• Tote bag inserts of company literature Manager, Business Development
• Padfolios 781-972-5483
• Keynote chair drop of company literature
• Session room chair drop of company literature jstroup@healthtech.com
• Program guide sponsor
• Poster abstract book sponsor
healthtech.com/SBD ••• 6

7. Hotel & Travel
Information Past Attendee
Testimonials:
“The selection of speakers and
Conference Venue and Hotel:
presentations strongly demonstrated
The Revere Hotel
the expansive breadth and impact of
structure-based drug design.”
- Director of Bioinformatics,
200 Stuart Street, Boston, MA 02116 ActivX Biosciences
Tel: (617) 482-1800
“Very, very interesting and useful.”
Discounted Room Rate: $249 s/d - Team Leader, Molecular Modelling,
Discounted Reservation Cut-off Date: May 17, 2013 CNRS-ICSN
Please visit our website to make your reservations “Good-quality up-to-date presentations
online, or call the hotel directly to reserve your made this a stimulating and informative
sleeping accommodations. You will need to identify conference.”
yourself as a Cambridge Healthtech Institute - CSO, De Novo Pharmaceuticals Ltd.
conference attendee to receive the discounted
room rate with the host hotel. Reservations made “Some discussions inspired new ideas I am
after the cut-off date or after the group room block going to try.”
has been filled (whichever comes first) will be - Senior Research Fellow, Merck
accepted on a space-and-rate-availability basis.
Rooms are limited, so please book early. “Thanks to the organizers, it’s a very
exciting conference. It’s very interesting
to listen to all the talks. Some discussions
inspired new ideas that I’m going to try!”
- Senior Research Fellow, Molsys, Merck
“Some important principles were
highlighted with regard to the computational
problem of describing ligand binding and
the computational problem of describing
Flight Discounts: ligand binding and drug-likeliness; and
the best thing was that the speakers could
Special discounts have been established with demonstrate that working solutions are
American Airlines. beginning to emerge.”
Please use one of the following methods: - Computational Chemist,
• Call American Airlines at 1-800-433-1790 and Bayer HealthCare
use Conference code 4463BU
“Some very important principles were
• Go to www.aa.com/group and enter 4463BU in highlighted and the best thing was that
the promotion discount box the speakers could demonstrate working
• Contact our dedicated travel agent, solutions.”
Rona Meizler at 1-617-559-3735 or - Computational Chemist, Bayer HealthCare
rona.meizler@protravelinc.com
“It was great – best conference I’ve been to.”
Car Rental Discounts: - Scientist, Prothana, Inc.
Special rental discounts have been established with “A useful meeting where I gained more
Hertz for this conference. insights and ideas to apply in my own
research.”
• Go to www.hertz.com and use our Hertz
- Chemistry Specialist,
Convention number (CV): 04KL0003
Catholic University Leuven
• Call Hertz at 1-800-654-3131 and use our
Hertz Convention Number (CV):04KL0003
healthtech.com/SBD ••• 7

8. Cambridge Healthtech Institute and Bio-IT World’s Thirteenth Annual
June 19-21, 2013
Structure-Based
The Revere Hotel
Boston, MA
Drug Design
Pricing and Registration Information
Receive a FREE eNewsletter by signing up
DINNER SHORT COURSE at chimediagroup.com
Academic, Government,
June 19 • 6:00pm-8:00pm Commercial Hospital-affiliated The latest industry news, commentary
and highlights from Bio-IT World
Structure-Based Drug Design for Epigenetic Targets $495 $295
Innovative management in clinical trials
Conference Pricing
(Excludes short course)
A series of diverse reports designed to
Early Registration until March 22, 2013 $1745 $845 keep life science professionals informed
of the salient trends in pharmaceutical
Advance Registration until May 10, 2013 $1895 $925 technology, business, clinical development,
and therapeutic disease markets.
Registrations after May 10, 2013, and on-site $2095 $995 For a detailed list of reports, visit
InsightPharmaReports.com, or contact
Rose LaRaia, rlaraia@healthtech.com,
+1-781-972-5444.
Special Package Pricing
(Includes access to Structure-Based Drug Design & Next-Gen Kinase Inhibitors, excludes short course)
Barnett is a recognized leader in clinical
Early Registration until March 22, 2013 $2995 $1495 education, training, and reference guides
for life science professionals involved in
Advance Registration until May 10, 2013 $3145 $1565 the drug development process. For more
information, visit barnettinternational.com.
Registrations after May 10, 2013, and on-site $3345 $1585
Conference Discounts
Cambridge Healthtech Associates™
(CHA™) uses its collaborative model to
Poster Submission-Discount ($50 Off) improve the speed and economics of life
Poster abstracts are due by May 10, 2013. Once your registration has been fully processed, we will send an email containing a unique link sciences R&D, leveraging its consulting,
allowing you to submit your poster abstract. If you do not receive your link within 5 business days, please contact jring@healthtech.com. technology evaluations and communities.
Visit www.chacorporate.com.
*CHI reserves the right to publish your poster title and abstract in various marketing materials and products.
International Society for Computational Biology (ISCB) Member- Discount 10% Off
Additional registration details
Subject to verification.
Each registration includes all conference
REGISTER 3 - 4th IS FREE: Individuals must register for the same conference or conference combination and submit completed registration form together
­ sessions, posters and exhibits, food
functions, and access to the conference
for discount to apply.
proceedings link.
Additional discounts are available for multiple attendees from the same organization. For more information on group rates, contact Handicapped Equal Access: In accordance
with the ADA, Cambridge Healthtech
David Cunningham at +1-781-972-5472.
Institute is pleased to arrange special
accommodations for attendees with
If you are unable to attend but would like to purchase the Structure-Based Drug Design CD for $350 (plus shipping), please visit www.healthtech.com/sbd. special needs. All requests for such
Massachusetts delivery will include sales tax. assistance must be submitted in writing
to CHI at least 30 days prior to the start
of the meeting.
Eleventh Annual To view our Substitutions/
BEST VALUE!
CO-LOCATED Next-Gen June 17-19
Register for both
conferences at a
Cancellations Policy, go to
http://www.healthtech.com/regdetails
Video and or audio recording of any kind
EVENT Kinase Inhibitors healthtech.com/KIN special rate.
is prohibited onsite at all CHI events.
Moving Towards a Successful Pipeline
How to Register: healthtech.com/sbd Please use keycode
SBD F
reg@healthtech.com • P: 781.972.5400 or Toll-free in the U.S. 888.999.6288 when registering!